[Methylprednisolone as an antiemetic in the chemotherapy of ovarian cancer]. / Metilprednizolon kao antiemetik uz kemoterapiju raka jajnika.

The authors examined the antiemetic effect of methylprednisolone (Lemod Solu) of the firm "Upjoh" in 35 patients with ovarian cancer in the course of the cisplatinum therapy. The control group comprised 15 patients with the same degree of ovarian cancer spreading in whom metoclopramide was used as the antiemetic. The antiemetic effect of methylprednisolone was found in the three fifths of patients having received the preparation from the first cisplatinum therapy cycle and in more than half of those in whom methylprednisolone was included in the second or third cisplatinum therapy cycle. The antiemetic effect of methylprednisolone proved to be significantly better than that of metoclopramide whose antiemetic effect was recorded in one fifth of the patients.

[Estrogen and progesterone receptors in ovarian carcinoma]. / Ispitivanje estrogenskih i progesteronskih receptora kod karcinoma jajnika.

Estrogen (ER) and progesterone (PR) receptors in 20 primary carcinomas of the ovary were studied by the customary DCC method. One of the receptors examined was found in 12 patients (60%) and both of them in 5 patients (25%). Serous types of tumour revealed a higher concentration of receptors than mucinous ones. The study of this kind is considered useful for the selection of patients in whom the adjuvant hormonal therapy could be applied.